Additional Prognostic Value of Tumor Grade Beyond the 21-gene Recurrence Score
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age20+
SponsorGangnam Severance Hospital
About this trial
To evaluated the prognostic significance of tumor grade in patients with node-negative, hormone receptor-positive, and human epidermal growth factor receptor 2-negative breast cancers treated according to RS-guided strategies.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients with hormone receptor-positive, HER2-negative early-stage breast cancer
Patients treated between January 2011 and December 2023
Patients with available clinicopathologic data and 21-gene Oncotype DX assay results confirmed through electronic medical records
Disqualifiers
Patients with breast cancer under the age of 20
Patients diagnosed with stage IV breast cancer
Patients for whom clinicopathologic data cannot be retrieved from electronic medical records
Trial population
Patients with HR-positive, HER2-negative breast cancer who were node-negative and underwent curative surgery followed by 21-gene Oncotype DX testing
Trial design
Design model
Cohort
Time perspective
Retrospective
Treatments tested in this trial
Tumor grade (I or II vs. III)
Other interventionWe compared the prognosis according to the tumor grade stratified by 21-gene recurrence score
Treatment groups
No treatment groups listed
Trial outcomes
Primary outcomes
1
Recurrence-free interval
Time frame
through study completion, an average of 5 yearLocations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: